Daily Hong Kong Stock Market News Express (Thursday, October 10)

USHK News
2024.10.10 01:05

Individual Stock News

  1. Country Garden (02007.HK): The contract sales in September were approximately RMB 3.62 billion, with a contracted sales area of about 420,000 square meters.

  2. Ping An Insurance (02318.HK): JP Morgan reduced its holdings by approximately 28.68 million shares on October 4th at an average price of HKD 56.7338 per share, involving about HKD 1.514 billion. After the reduction, JP Morgan's latest holding is approximately 602 million shares, reducing its stake from 8.08% to 7.72%.

  3. Haier Smart Home (06690.HK): JP Morgan increased its holdings by approximately 7.27 million shares on October 4th at an average price of HKD 34.0781 per share, involving about HKD 2.48 billion. After the increase, JP Morgan holds approximately 256 million shares, increasing its stake from 8.95% to 9.21%.

  4. J&T EXPRESS-W (01519.HK): Achieved a parcel volume of 17.254 billion in the first three quarters, a year-on-year increase of 30.4%.

  5. AKESO (09926.HK): The innovative drug for gastric cancer indications has been approved for listing, with two dual-antibody drugs participating in medical insurance negotiations.

  6. Guotai Junan Securities (02611.HK) and Haitong Securities (06837.HK) jointly announced that the A-shares and H-shares of Guotai Junan Securities and Haitong Securities are planned to be exchanged at the same exchange ratio of 0.62:1. After meeting all proposed merger conditions, Haitong Securities will also apply to voluntarily withdraw the listing status of relevant Haitong Securities shares on the Hong Kong Stock Exchange and the Shanghai Stock Exchange.

  7. Jiangxi Copper (00358.HK) announced that the Board received a written resignation letter from independent non-executive director Mr. Li Shuidi on October 9, 2024.

  8. INNOCARE (09969.HK): ICP-488 (a once-daily oral TYK2 (tyrosine kinase 2) decoy inhibitor) achieved positive trial results in a Phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis

Source: USHK News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.